Envisagenics Inc.

https://www.envisogenics.com

LinkedIn: https://www.linkedin.com/company/envisagenics

Envisagenics is an Artificial Intelligence-driven biotechnology company that focuses on the discovery of novel RNA splicing variants that cause cancer and other genetic diseases. Its principal technology is the SpliceCore® discovery platform. The platform re-envisions the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing. It is up to 250 times more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing events that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders. Envisagenics partners with biopharmaceutical companies and academic institutions to advance their drug discovery capabilities. Envisagenics also has its own internally developed RNA therapeutic programs. Envisagenics is a spin-out of Cold Spring Harbor Laboratory and a proud woman- and minority-led recipient of several grants from the National Institute of General Medical Sciences and the National Cancer Institute. *

	Start	2014-04-22 established (s-off)
	Predecessor	Cold Spring Harbor Laboratory (CSHL)
	Industry	AI-based drug discovery / AI-based drug development
	Industry 2	artificial intelligence (AI) / machine learning (ML)
	Person	Pineda, Maria Luisa (Envisagenics 202211 CEO + Co-Founder)
	Person 2	Akerman, Martin (Envisagenics 202211 CTO + Co-Founder)

	Region	New York, NY
	Country	United States (USA)
	Street	30-02 48th Avenue Suites 140 and 150
	City	11101 Long Island City, New York, NY
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Envisagenics, Inc.. (11/29/22). "Press Release: Envisagenics Announces Research Collaboration with Bristol Myers Squibb". New York, NY.

		Record changed: 2023-07-10